ArticleEpidemiology and infection2020
Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19).
Article in Epidemiology and infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Serum Prealbumin Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.Frontiers in immunologyPooled it
- Comparative immunologic profiling of mRNA and protein-conjugated vaccines: acute inflammatory responses and anti-PEG antibody production.Animal cells and systems · 2025Article
- Acute-phase proteins as indicators of disease severity and mortality in COVID-19 patients.Scientific reports · 2024Article
- The Association of Serum Profile of Transferrin Isoforms with COVID-19 Disease Severity.Journal of clinical medicine · 2024Article
- Dissociation Phenomenon of Erythrocyte Agglutination and Its Application to Assay of Functional Activity of the Complement System in Clinical Laboratory.Journal of clinical laboratory analysis · 2024Article
- Aging is associated with an insufficient early inflammatory response of lung endothelial cells in SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- Article
- Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.Immunobiology · 2023Review
- Serum biomarkers for nutritional status as predictors in COVID-19 patients before and after vaccination.Journal of functional foods · 2023Article
- Serum amyloid A-A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19.Frontiers in medicine · 2023Review
- Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19.Glycobiology · 2022Article
- Acute kidney injury associated to COVID-19 leads to a strong unbalance of circulant immune mediators.Cytokine · 2022Article
- High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19.JPEN. Journal of parenteral and enteral nutrition · 2022Article
- Decision support analysis for risk identification and control of patients affected by COVID-19 based on Bayesian Networks.Expert systems with applications · 2022Article
- SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS.Frontiers in immunology · 2022Article
- Corticosteroids for COVID-19.Journal of intensive medicine · 2021Review
- Efficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumonia.Journal of medical virology · 2021Article
- Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential.Frontiers in physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of 2019 novel coronavirus disease (COVID-19) is currently a global concern. In this study, our goal was to explore the changing expression levels of acute-phase reaction proteins (APRPs) in the serum of COVID-19 patients and to elucidate the immunological characteristics of COVID-19. In the study design, we recruited 72 COVID-19 patients, including 22 cases of mild degree, 38 cases of moderate degree and 12 cases of severe degree. We also recruited 20 patients with community-acquired pneumonia (CAP) and 20 normal control subjects as a comparison. Fasting venous blood was taken to detect the content of complement 3 (C3), complement 4 (C4), C-reactive protein (CRP), serum amyloid A (SAA) and prealbumin (PA). When compared the COVID-19 group with the CAP and normal control groups, respectively, the mean value of CRP and SAA in the COVID-19 group (including mild, moderate and severe patients) had increased significantly (P < 0.01), whereas the mean values of C3, C4 and PA decreased (P < 0.01). For the asymptomatic or mild symptomatic patients with COVID-19, the actual aggravation of disease may be more advanced than the clinical appearances. Meanwhile, the statistical analyses indicated that the development of COVID-19 brought about a significant increase in the content of CRP and SAA (P < 0.01), and a decline in the content of C3, C4 and PA (P < 0.01). These findings suggested that the changes in the level of APRPs could be used as indicators to identify the degree and progression of COVID-19, and the significant changes might demonstrate the aggravation of disease. This study provided a new approach to improve the clinical management plan and prognosis of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.